Diabetes, Obesity and Atrial Fibrillation: Epidemiology, Mechanisms and Interventions

Asghar O[1], Alam U[1], Hayat SA[2], Aghamohammadzadeh R[1], Heagerty AM[1], Malik RA[1]

[1]Division of Cardiovascular Sciences, The University of Manchester, UK. [2]Department of Cardiology, Imperial College Healthcare NHS Trust, London, UK

Abstract

Body mass index (BMI) is a powerful predictor of death, type 2 diabetes (T2DM) and cardiovascular (CV) morbidity and mortality. Over the last few decades, we have witnessed a global rise in adult obesity of epidemic proportions. Similarly, there has been a parallel increase in the incidence of atrial fibrillation (AF), itself a significant cause of cardiovascular morbidity and mortality. This may be partly attributable to advances in the treatment of coronary heart disease (CHD) and heart failure (HF) improving life expectancy, however, epidemiological studies have demonstrated an independent association between obesity, diabetes and AF, suggesting possible common pathophysiological mechanisms and risk factors. Indeed, cardiac remodeling, haemodynamic alterations, autonomic dysfunction, and diastolic dysfunction have been reported in obese and diabetic cohorts. Moreover, diabetic cardiomyopathy is characterized by an adverse structural and functional cardiac phenotype, which may predispose to the development of AF. In this review, we discuss the pathophysiological and mechanistic relationships between obesity, diabetes and AF, and some of the challenges posed in the management of this high-risk group of individuals.

Introduction

Obesity, Metabolic Syndrome and AF Risk

The link between obesity and AF was first recognized in retrospective analyses of incident AF in peri-operative cardiac surgical patients.[1-4] These early observations were subsequently supported by data from several large cohort studies. The first prospective study of incident AF was undertaken in subjects from the Framingham cohort, in which there was a 4-5% increase in AF risk for every unit increase in BMI, over a mean duration of 13.7 years.[5] Furthermore, this association remained unchanged even after adjusting for myocardial infarction (MI), hypertension (HT) and diabetes (DM), and increased across the range of obesity. In the same study, obesity was also associated with an increase in left atrial diameter, a recognized precursor of AF. However, the relationship between BMI and AF was lost following adjustment for left atrial size, suggesting AF risk in obese subjects is mediated through left atrial enlargement, a finding which has also been reported in subjects with the metabolic syndrome (MetS).[6,7]

Indeed, left atrial enlargement is present in a significant proportion of obese adolescents and adults and is attenuated following weight reduction.[8,9] In the MONICA/KORA study, age, obesity and HT were independently associated with left atrial enlargement over a ten-year period; obesity being the most powerful predictor (OR: 2.4 vs. 2.2; p<0.001) and the combination of obesity and HT demonstrated the greatest LA enlargement.[10] Other large prospective studies have reported comparable AF risk, for example in the Danish Diet, Cancer and Health study of 47,589 individuals followed up over a mean duration of 5.7 years, the incidence of AF/flutter was 1.2%, two thirds of which occurred in males.[11] The adjusted hazard ratios (HR) for AF/flutter were 2.35 (95% CI 1.70-3.25) and 1.99 (95% CI 1.31-3.02) in obese men and women respectively. In a recent meta-analysis, obesity was associated with a 49% increased risk of AF (RR 1.49, 95% CI 1.36-1.64) in 6 population studies, but no association was reported in post cardiac surgery studies (RR 1.02, 95% CI 0.99-1.06).[12] Similarly, in the long term follow up of the Atherosclerosis Risk in Communities (ARIC) study cohort, 17.9% of incident AF was attributed to obesity. In a long term follow up study of Swedish men; BMI and BSA in youth were associated with AF risk with an increased risk of progression from paroxysmal AF to permanent AF.[13] In the Women's Health Study of over 34,000 female healthcare professionals free of CVD, the investigators reported a linear relationship between BMI and AF characterized by a 4.7% (95% CI: 3.4-6.1% p<0.0001) increased risk of AF for every 1 unit increase in BMI.[14] This association was maintained whichever classification of obesity was used and after adjusting for confounding variables and inflammatory markers. Importantly, a change in weight

Disclosures:
None.

Corresponding Author:
Professor R A Malik, MBChB, FRCP, PhD,
Professor of Medicine, Consultant Physician,
Centre for Endocrinology, Diabetes
Institute of Human Development,
Faculty of Medical, Human Sciences,
CMFT and University of Manchester,
Core Technology Facility,
46 Grafton Street, Manchester, M13 9NT.

category during the first 5 years of follow up was associated with a corresponding change in AF risk. This risk was marginally greater in subjects who progressed from the non-obese (BMI ≤ 30) to obese (BMI ≥30) weight category than those who were obese at baseline and follow up (RR 1.41 vs. 1.32). Weight reduction from obese to non-obese was associated with a risk reduction to that of non-obese subjects at baseline. These findings would imply that AF risk in obese individuals is reversible, achievable through interventions such as weight reduction. Furthermore, the lower risk observed at follow up in the group who were obese at baseline supports the concept of an obesity paradox which has been reported in previous studies such as the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) trial in which obese patients with AF had favourable outcomes compared with their non-obese counterparts.[15,16] Clearly, further studies are required to investigate this phenomenon.

Although there is considerable overlap with obesity, Met S is generally considered to be a constellation of risk factors specific to the development of atherosclerotic cardiovascular disease and T2DM and is characterized by abdominal obesity, dyslipidaemia, HT and glucose intolerance.[17] Few robust studies have been carried out in MetS cohorts to assess AF risk. In the Niigata study, subjects with MetS had an increased risk of AF which was independently associated with age and obesity, irrespective of the definition of MetS used (AHA/NHLBI vs. NCEP-ATPIII).[18] In multivariate models for individual components of the MetS, BMI and HT contributed the most to AF risk and interestingly, low HDL cholesterol was also strongly associated. In addition, AF risk was positively correlated with the number of MetS components exhibited, further supporting the notion that MetS simply represents a clustering of risk factors.[19] In a recent study of the Framingham Offspring cohort, the relationship between insulin resistance (IR) and incident AF in non-diabetic subjects was investigated over ten years of follow up.[20] Both adjusted (HR 1.27, 95% CI 0.92 to 1.76, p=0.15) and unadjusted (HR 1.10, 95% CI 0.83 to 1.45, p=0.52) analyses failed to demonstrate an association between IR and AF.

Although the mechanistic basis for the relationship between obesity, LA enlargement and AF is not completely understood, it is likely to be multifactorial involving haemodynamic disturbances, autonomic dysfunction and induction of the renin-aldosterone-angiotensin-system (RAAS), resulting in mechanical and electrical remodeling of the left atrium.

Diabetes and AF Risk

Several studies have reported an association between DM and AF.[21,22] In the ARIC study, the incidence of AF in diabetic subjects was double that of non-diabetic subjects.[23] Furthermore, DM but not pre-diabetes was associated with an increased AF risk (HR 1.35, 95% CI 1.14-1.60) which was independently associated with fasting glucose and HbA1c. In a recent meta-analysis, DM was associated with an increased AF risk (RR 1.39, 95% CI 1.10-1.75, p <0.001), which remained significant after correction for publication bias and multiple risk factors (RR 1.24, 95% CI 1.06-1.44, vs. 1.70, 1.29-2.22, p = 0.053).[24]

Adipocytokines – the Link between Fat, Inflammation and AF

C-reactive protein (CRP) levels are increased in patients with persistent AF compared to controls and subjects with paroxysmal AF (PAF), thus suggesting a possible link between inflammation and AF.[25-27] A building literature supports the role of adipose tissue mediated inflammation and the development of AF. Recent work on visceral adipose tissue has focused on the role of epicardial fat in the pathogenesis of AF as epicardial fat thickness correlates strongly with visceral fat on magnetic resonance imaging.[28-30] Individuals with permanent AF have a greater volume of epicardial fat compared with individuals with PAF, and those with either PAF or permanent AF have a greater volume of pericardial fat compared with controls.[31] This difference is predominantly related to atrial adiposity as opposed to periventricular epicardial fat thickness, which is comparable between all groups.[32] More specifically, adipose tissue thickness in the inter-atrial septum is positively correlated with BMI and left atrial volume and inversely correlated with plasma adiponectin levels.[32] Epicardial fat thickness is associated with an increased risk of AF whereas pericardial fat is predictive of LA volume in addition to AF prevalence, severity and poorer outcomes following catheter ablation.[33,34]

The effects of epicardial fat on the heart are mediated through a group of cytokines produced by adipocytes known as adipocytokines which possess inflammatory, anti-inflammatory and vasoactive properties implicated in the pathogenesis of several cardiovascular diseases.[30,35] Several adipocytokines have been associated with AF including adiponectin, resistin, a pro-inflammatory cytokine associated with insulin resistance, and more recently, YKL-40, a general marker of inflammation.[36-38] Adiponectin levels are reduced in obesity and T2DM and increase following weight loss.[39,40] Ybarra et al studied the relationship between LA size and adiponectin in obese subjects.[41] Adiponectin levels significantly correlated with indices of glycaemia, insulin and lipids and were significantly lower in both obese subjects and in obese subjects with an enlarged LA. The association with LA size persisted after adjustment for the homeostasis model assessment of insulin resistance (HOMA-IR), age, sex, and LV mass. Few studies have investigated the relationship between adipocytokines and AF. In a study of the Framingham offspring cohort, plasma resistin concentration was significantly associated with incident AF (HR 1.17, 95% CI 1.02-1.34, p=0.028), however this relationship was lost after adjustment for CRP[42] and adiponectin concentration did not predict incident AF. In contrast, adiponectin appears to have a protective effect following cardiac surgery.[43,44] YKL-40 is associated with AF recurrence following catheter ablation, but did not predict successful cardioversion in patients with AF.[45,46] In a Japanese study, adiponectin levels were elevated in patients with persistent AF compared to those with paroxysmal AF and controls.[47] The significance of such findings is unclear and further studies are required to determine the relationship between adipocytokines and AF.

The association between inflammation and AF has also been established via mechanistic in vitro studies.[26,48] Inflammatory changes have been observed in atrial tissue from patients with lone AF[49] and at the cellular level, NAD(P)H oxidase activity and nitric oxide synthase uncoupling in the myocardium have been proposed as sources of free radicals contributing to oxidative stress in the atrial myocardium of patients with AF.[50] Whole-cell patch clamp studies of pulmonary vein cardiomyocytes have demonstrated that TNF-α incubation leads to altered calcium homeostasis and enhanced arrhythmogenicity.[51]

Autonomic Dysfunction and the Atrial Substrate

Cardiac autonomic neuropathy (CAN) the commonest manifestation of diabetic autonomic neuropathy (DAN), may be present during the pre-diabetic phase, and is a strong independent risk factor for morbidity and mortality.[52] This risk may be attributable to features of advanced CAN including sudden cardiac death (SCD), cardiac arrhythmias, silent myocardial ischaemia and lack of hypoglycaemia awareness.[53] Hypoglycaemia has been associated with an increased mortality risk which may be attributable to the pro-arrhythmic effects of hypoglycaemia on the QT interval.[54] However, despite the increased incidence of hypoglycaemia and mortality in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, there were fewer arrhythmia related deaths both during intensive treatment and following termination of this arm of the study.[55] AF risk is increased in diabetic subjects and this risk increases with diabetes duration and worsening glycaemic control.[22,56] Although the exact role of glycaemia in the progression of CAN is not fully understood, several large clinical trials have demonstrated the beneficial effects of glycaemic control and multifactorial cardiovascular intervention on delaying the onset of CAN.[57] CAN is also associated with coronary microvascular dysfunction and diastolic dysfunction in diabetic subjects.[58,59]

The cardiac autonomic nerves play a key role in the regulation of heart rate and an imbalance in autonomic tone can give rise to electrophysiological effects which may predispose to the development of AF.[60] The sino-atrial (SA) node and atrio-ventricular (AV) node are both influenced by autonomic tone, and vagal stimulation can result in marked changes in cardiac electrophysiology, including heterogeneous effects on the atrial refractory period (ARP), pacemaker activity and AV conduction.[61,62] Increased vagal tone also contributes to the genesis of so called 'vagal AF', a phenomenon that is thought to play a key role in a subset of patients in whom primarily vagal abnormalities contribute to AF.[63,64]

Sympathetic over-activity on the other hand, may precipitate AF and occurs following the induction of the RAAS. Increased levels of angiotensin II and decreased levels of the neuropeptide, substance P, are associated with post-operative AF incidence in patients undergoing CABG, thus implicating the role of sympathetic over-activity and reduced parasympathetic activity, respectively in the pathogenesis of AF.[65] Despite the early promise for the use of RAAS inhibitors in the prevention of AF, subsequent trials and meta-analyses have shown no benefit.[66] Another important manifestation of RAAS activation is myocardial fibrosis, which is mediated through pro-fibrotic agents such as angiotensin II and results in both electrical and mechanical remodeling of the left atrium predisposing to AF.[67,68]

Neural remodeling is thought to play a crucial role in increased AF vulnerability in DM and experimental models have shown alterations in sympathetic nerves in the right atrium with AF being enhanced by adrenergic activation.[69,70] Aberrant neurotransmission seems to be a key feature of arrhythmogenicity and a recently published study showed alterations in purinergic neurotransmission in the atria of diabetic rats.[71] AF may also be provoked in individuals with PAF and normal autonomic function by isoprenaline implying an increased susceptibility despite normal cardiovascular reflexes.[72] In addition, symptoms of dizziness at the onset of paroxysmal AF may be predicted by impaired autonomic function[73] suggesting a key role in the symptomatology noted in some patients. Alterations

in autonomic tone also manifest themselves in chronic AF and the degree of dysfunction may be a method of risk stratification for SCD and HF.[74]

The ECG provides a quick and readily accessible tool for the assessment of cardiac conduction and is of particular value in those with DM and DAN.[75] CAN may cause an increase in p-wave duration and dispersion and hence the ECG may be a useful tool for the prediction of AF.[76]

The Pro-Thrombotic State: Added Risk of Thrombosis?

Individuals with AF are at significant risk of thromboembolic complications, most notably stroke. This risk is increased in the presence of co-existing obesity, MetS or DM. The reported incidence of stroke in patients with DM and AF ranges between 3.6 and 8.6% per year.[77] The higher incidence of thrombotic and thromboembolic events observed in these high risk groups may be attributable to a pro-thrombotic state. Indeed, obesity and DM predispose to thrombosis by adversely affecting all components of Virchow's triad,[78,79] particularly hypercoagulability, characterized by platelet activation, increased production and activation of clotting factors, hyperviscosity, and diminished fibrinolysis.[80-82]

In DM, circulating glucose exerts pro-thrombotic effects through several different mechanisms. Hyperglycaemia potentiates coagulation through elevated levels of thrombin-antithrombin complexes and soluble TF.[83,84] Advanced glycation end products (AGE) induce TF mRNA expression and lead to increased TF levels.[85,86] Factor VII levels also increase following induced-hyperglycaemia in both diabetic and non-diabetic subjects, and return to normal once euglycaemia is established.[87] Relative plasma viscosity (RPV) is also increased in diabetic subjects compared to healthy controls and increases progressively with worsening glycaemic control.[88] Insulin enhances PAI-1 production in adipocytes and hyperinsulinaemia results in elevated PAI-1 levels, thus attenuating the fibrinolytic pathway.[83,89]

Enhanced platelet activation is observed in subjects with MetS and DM through altered adipokine levels, increased thromboxane B(2) and activation of the platelet glycoprotein IIb/IIIa receptor.[90,91] Leptin, an adipokine with predominantly nitric oxide-dependent vasodilator properties is elevated in obese subjects.[92] Platelets express the Leptin receptor and the leptin-receptor complex results in promotion of platelet aggregation via synergistic action with adenosine diphosphate.[93] Adiponectin also plays a role in platelet aggregation, as knock-out animal models exhibit enhanced thrombus formation which is reversed by the delivery of adenovirus-mediated adiponectin.[94] Plasma adiponectin has been shown to be inversely correlated with platelet aggregation in patients with T2DM, HT or hypercholesterolaemia.[95]

Interventions in AF

Stroke Risk in AF

The risk of thromboembolic complications and stroke in AF is non-linear. A number of risk factors have been identified that increase stroke risk in AF in a cumulative manner and have been incorporated into formal stroke risk stratification schemes to aid clinicians. Over the past decade, these schemes have had a modest predictive value for stroke and thromboembolism, especially when patients are categorized into low, moderate, and high risk groups.[97] The main purpose for this risk stratification was to identify 'high

risk' patients who might benefit from oral anticoagulant therapy in spite of its relative inconvenience. These risk categories however are essentially artificial divisions of a continuous spectrum of stroke risk, especially in the presence of multiple stroke risk factors.[97,98] As such, the 2010 European Society of Cardiology (ESC) guidelines relaxed the emphasis on categorizing patients into low, moderate or high stroke risk by promoting an approach based on individual risk factors.[98]

To complement the simple and extensively used CHADS$_2$ (Congestive heart failure, Hypertension, Age >75 and Diabetes and Stroke/TIA) score, the ESC guidelines recommend the use of the newer CHA$_2$DS$_2$-VASc scheme[97,98] emphasizing a more robust stroke risk assessment, and to help identify those who are truly 'low risk'.

Unlike DM, obesity and MetS are not considered specific risk factors in such risk stratification schemes however there is some evidence to suggest they should. In a study examining the risk of left atrial thrombus in patients with AF, subjects with a BMI ≥ 27 had a markedly increased risk of left atrial appendage thrombus (OR 4.02 CI 95% 1.19-13.55, p=0.025).[99]

Rate vs. Rhythm Control

Rate Control

Rate-control treatment is based on pharmacological depression of conduction through the atrioventricular node. Three classes of drugs are commonly used for rate-control treatment: β-blockers, such as metoprolol or bisoprolol, non-dihydropyridine calcium antagonists (verapamil, diltiazem) and digoxin. In the absence of pre-excitation, β-blockers are first-choice drugs to reduce the heart rate. Traditionally, there has been a reluctance to use β-blockers in patients with DM for fear of adverse effects on insulin resistance and an unawareness of hypoglycaemia. However, given the overall benefits of β-blockers in HF and CHD, conditions that are prevalent amongst diabetic patients, the recommendations regarding β-blockade remain the same. Clearly, intolerance in individuals should prompt switching to an alternative.

There is some emerging animal data which suggests that calcium channel blockers, such as a verapamil, may prevent loss of functional β-cell mass.[100] It has recently been identified that thioredoxin-interacting protein (TXNIP) may be a potential target to prevent loss of functional β-cell mass. Glucose and DM upregulate β-cell TXNIP expression, and TXNIP overexpression induces β-cell apoptosis. In contrast, genetic ablation of TXNIP promotes endogenous β-cell survival and prevents streptozotocin (STZ) and obesity-induced DM. Xu et al. have demonstrated that calcium channel blockers inhibit TXNIP expression in INS-1 cells and human islets. Also, orally administered verapamil reduced TXNIP expression and β-cell apoptosis, enhanced endogenous insulin levels, and rescued mice from STZ-induced DM. Furthermore, verapamil promoted β-cell survival and improved glucose homeostasis and insulin sensitivity in BTBR ob/ob mice. If human studies support these findings then calcium channel blockers may became the drug group of choice in diabetic patients without co-existing HF or CHD.

In patients who fail to respond to rate limiting drugs, non-pharmacological measures such as atrioventricular nodal ablation may be considered.[101]

Rhythm Control

Up to 50% of patients with recent onset AF revert back to sinus rhythm spontaneously.[98] If the patient does not revert spontaneously, they can be considered for either pharmacological or electrical cardioversion, especially for those who remain symptomatic despite adequate ventricular rate control. In patients with structural heart disease, such as CHD and systolic left ventricular dysfunction, class I antiarrhythmic drugs, including flecainide and propafenone, are contraindicated because of the potential increased proarrhythmia risk.[98]

Amongst diabetic patients this can limit the options for drug therapy due to the higher incidence of HF and CHD. There is no data in the literature to indicate whether commonly used anti-arrhythmic medications to achieve cardioversion or maintain sinus rhythm are any less effective amongst diabetic or obese patients and therefore should be considered, bearing in mind the previously mentioned caveats. However, obesity has been implicated in a number of studies as a predictor of failed electrical cardioversion and earlier recurrence of AF.[102-104] By virtue of the high prevalence of obesity amongst diabetic patients, as high as 52% in T2DM in some cohorts,[105] the more modest success rates in those with BMI >30 should be considered when deciding on management strategy. In those obese patients who fail external DC cardioversion, further options are: higher energy;[106] antero-posterior positioning of paddles;[107] fluoroscopy guided positioning of defibrillation paddles;[108] or internal DC cardioversion.[109]

It should be emphasised that whatever strategy is chosen, the patient must be evaluated for long-term antithrombotic prophylaxis according to his/her risk profile.

Patient-Tailored Therapy

The decision to add rhythm control therapy to the management of AF requires an individual decision and should therefore be discussed at the beginning of AF management and revisited depending on response to treatment/side effects. Before choosing rate control alone as a long-term strategy, the physician should consider how permanent AF is likely to affect the individual patient in the future and how successful rhythm control is anticipated to be. AF related symptom burden is a key determinant in influencing the decision to opt for rate or rhythm control in addition to factors that may influence the likely success of a rhythm control strategy. These include a long history of AF, older age, more severe associated cardiovascular diseases, other associated medical conditions, and enlarged LA size.

The relatively low efficacy of prophylactic antiarrhythmic agents and the incidence of their potentially proarrhythmic effects has promoted the development of non-pharmacological strategies for prevention and control of AF, based on surgical or radiofrequency ablation.

Catheter Ablation of AF in Patients with Diabetes

The increased prevalence of CHD in patients with T2DM often restricts the use of class Ia and Ic antiarrhythmic agents. As such, they may potentially glean a greater symptom benefit from ablation. There are now randomised data evaluating efficacy of catheter ablation in patients with T2DM.[110-112] From their study cohort of 263 patients Tang et al. compared those with T2DM (n=31) against those without (n=232).[112] Although AF recurrence rates were not significantly different between the two groups, the trend suggested higher recurrence in patients with T2DM, 32.3% vs. 22.4% (p=0.24). This trend was to be expected given the important differences in

clinical baseline characteristics: age (62.0 ± 10.8 vs. 56.1 ±10.6 years, P = 0.004), longer AF history (9.6 ± 9.3 vs. 6.7 ± 6.3 years, p=0.024), significantly larger left atrium size (41.1 ± 7.8 vs. 38.3 ± 5.8 mm, p=0.021), HT (58.1 vs. 35.8%, p=0.018) and structural heart disease (67.7 vs. 43.5%, p=0.011). Patients with DM also experienced a higher rate of complications, 29.0% vs. 8.2%, p=0.002). Forleo et al. randomized patients with T2DM to either radiofrequency ablation or anti-arrhythmic therapy[111] Over a 12-month follow up period they found that AF recurrence rates were higher in the non-ablation arm (57.1% vs. 20%, p=0.001). Unlike Tang et al., complication rates were comparable to previous published data for left atrial catheter ablation.

A more recent study compared AF patients with abnormal glucose metabolism (T2DM or IGT) against those without.[110] They found that the substrates for AF differed significantly between the groups: Left atrial (108.4 ± 22.3 vs. 94.0 ± 17.5ms, p <0.001) total activation times were significantly longer in the patients with AF and an abnormal glucose metabolism compared to those normal glucose metabolism. Furthermore, left atrial (1.48±0.74 vs. 2.05±0.78mV, p<0.001) bipolar voltages were also significantly lower in those with AF and abnormal glucose metabolism. Not unexpectedly, these adverse substrate changes had an impact on AF recurrence rates. Over a follow up period of 18±6.4 months the AF recurrence rate was significantly greater in patients with abnormal glucose metabolism (18.5% vs. 8.0%, p<0.022). Complex fractionated atrial electrograms (CFAE) are well documented to be an important factor in the maintenance of AF in persistent AF. This has led to most electrophysiologists incorporating CFAE ablation as an integral component of ablation in addition to pulmonary vein isolation (PVI) and linear left atrial ablation. CFAE in persistent AF tend to occur in localised areas within the left atrium of slow conduction and low voltage amplitude signals thought to be related to atrial fibrosis.[113] Although there is no data in the literature reporting an increased burden of CFAE in diabetic patients, this is likely, given Chao et al.'s findings of significantly lower left atrial activation times and bipolar voltages in patients with DM/impaired glucose tolerance.[110] There may well be a case for adopting similar ablation strategies in diabetic patients with PAF, as are currently used in persistent AF cases, in an effort to reduce AF recurrence.

Catheter Ablation of AF in Obese Patients

Success rates with catheter ablation in obese versus non-obese patients is comparable without a significant increase in complications. Mohanty et al. compared patients with a BMI of <25 and those ≥25 and demonstrated comparable freedom from AF at 12 months (69% vs. 63%, p=0.109, respectively). [162] Interestingly, patients in the obese category reported a greater improvement in quality of life (QoL) scores compared to non-obese patients. This was, at least in part, due to their worse baseline QoL scores. In multivariable analysis BMI ≥25 and baseline QoL were independent predictors of QoL improvement. However, others have found that obesity and metabolic syndrome were independent predictors of late recurrence of AF.[114]

Catheter ablation appears to be an effective treatment in patients with DM, obesity or both and they appear to have more to gain in terms of symptomatic improvement. However, although there is potentially a greater symptom benefit to be gained by obese patients from catheter ablation, and small studies demonstrating comparable procedural risk, in practice, most electrophysiologists will choose not to ablate very obese patients. Catheter ablation in these patients can prove very challenging; venous access is frequently difficult, fluoroscopic imaging is often suboptimal and even sedation/general anaesthesia proves much more challenging.

Upstream Therapies

Increasing evidence has shown that AF development and perpetuation depend on both electrophysiological and structural remodeling of the atrium.[115] Inflammation and oxidative stress have been linked to atrial remodeling and have also been implicated with AF recurrence after catheter ablation.[116-118] The potential beneficial effects of anti-inflammatory and antioxidant drugs such as statins, RAAS inhibitors and corticosteroids, on AF recurrence after catheter ablation has attracted much interest over the last 5 years.[117-120] Unfortunately, their potential has remained unfulfilled; angiotensin-converting enzyme inhibitors, ARBs and statins have failed to show any reduction in AF recurrence.[121-123] Omega-3 polyunsaturated fatty acid supplementation has not been definitively shown to have a positive impact on incidence or recurrence of AF. In fact, the weight of evidence is mostly against any benefit.[124-127]

A recent 150 patient prospective observational study examined the effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal AF and T2DM.[128] Consecutive patients undergoing catheter ablation were divided into those who received pioglitazone before ablation or not. 51 patients treated with pioglitazone and 99 control subjects were followed up for at least 15 months after ablation. After a single ablation, sinus rhythm was maintained in 44 patients (86.3%) in the pioglitazone group vs. 70 patients (70.7%) in the control group (p=0.034), without antiarrhythmic drug during a mean follow-up of 22.9 ± 5.1 months. The second ablation was performed in 5 patients (9.8%) from the pioglitazone group and in 24 patients (24.2%) from the control group (p=0.034). Pioglitazone is a peroxisome proliferator activated receptor-gamma (PPARγ) agonist and represents a class of anti-diabetic agents that reduce insulin resistance mainly by activating PPARγ. Accumulating evidence suggests that PPARγ agonists exert modulatory effects on growth factor release, cell proliferation and migration, extracellular matrix remodeling, and cell cycle progression and differentiation.[129] Experimental evidence demonstrates that PPARγ agonists inhibit macrophage activation and the associated inflammatory cytokines[130] as well as suppress superoxide production and induce antioxidant enzymes.[115] Additionally, clinical studies suggest that PPARγ agonists reduce C-reactive protein (CRP) levels in diabetic and non-diabetic patients, independently of glycaemic control.[131] But of course it is important to remember that these drugs are contraindicated in NYHA class III and IV HF and therefore in the context of patients with AF and HF will have limited use. Furthermore because PPARγ agonists cause weight gain, which can increase AF risk, the use of this class of drugs would not be recommended.

Bariatric surgery is the most reliable way of achieving and maintaining significant weight loss in morbidly obese individuals and is being performed in rapidly growing numbers across the globe[132,133] Weight loss secondary to bariatric surgery or lifestyle modification may reverse the hypercoagulable state in obesity by a reduction in thrombin generation and PAI-1 and TF levels.[26,134] Clearly, there is a need for additional studies to further establish the most cost-effective interventions to reduce the pro-thrombotic state and stroke risk.

Conclusions:

Obesity, MetS and DM through a complex interplay of metabolic, inflammatory and neural mechanisms, create an environment conducive to AF and pose unique challenges in the treatment of this common arrhythmia. In addition, the presence of a pro-thrombotic state requires targeted therapeutic interventions if we are to avoid an epidemic of stroke associated with AF. Current evidence challenges the traditional paradigm, which excludes obesity for risk stratification in AF.

References:

1. Sumeray M, Steiner M, Sutton P, et al. Age and obesity as risk factors in perioperative atrial fibrillation. Lancet. 1988 Aug 20;2(8608):448.

2. Zacharias A, Schwann TA, Riordan CJ, et al. Obesity and risk of new-onset atrial fibrillation after cardiac surgery. Circulation. 2005 Nov 22;112(21):3247-55.

3. Echahidi N, Mohty D, Pibarot P, et al. Obesity and metabolic syndrome are independent risk factors for atrial fibrillation after coronary artery bypass graft surgery. Circulation. 2007 Sep 11;116(11 Suppl):I213-9.

4. Girerd N, Pibarot P, Fournier D, et al. Middle-aged men with increased waist circumference and elevated C-reactive protein level are at higher risk for postoperative atrial fibrillation following coronary artery bypass grafting surgery. Eur Heart J. 2009 May;30(10):1270-8.

5. Wang TJ, Parise H, Levy D, et al. Obesity and the risk of new-onset atrial fibrillation. Jama. 2004 Nov 24;292(20):2471-7.

6. Nicolaou VN, Papadakis JE, Karatzis EN, et al. Impact of the metabolic syndrome on atrial size in patients with new-onset atrial fibrillation. Angiology. 2007 Feb-Mar;58(1):21-5.

7. Umetani K, Kodama Y, Nakamura T, et al. High prevalence of paroxysmal atrial fibrillation and/or atrial flutter in metabolic syndrome. Circ J. 2007 Feb;71(2):252-5.

8. Garza CA, Pellikka PA, Somers VK, et al. Major weight loss prevents long-term left atrial enlargement in patients with morbid and extreme obesity. Eur J Echocardiogr. 2008 Sep;9(5):587-93.

9. Hirschler V, Acebo HL, Fernandez GB, et al. Association between left atrial size and measures of adiposity among normal adolescent boys. Pediatr Cardiol. 2012 Feb;33(2):245-51.

10. Stritzke J, Markus MR, Duderstadt S, et al. The aging process of the heart: obesity is the main risk factor for left atrial enlargement during aging the MONICA/KORA (monitoring of trends and determinations in cardiovascular disease/cooperative research in the region of Augsburg) study. J Am Coll Cardiol. 2009 Nov 17;54(21):1982-9.

11. Frost L, Hune LJ, Vestergaard P. Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Med. 2005 May;118(5):489-95.

12. Wanahita N, Messerli FH, Bangalore S, et al. Atrial fibrillation and obesity--results of a meta-analysis. Am Heart J. 2008 Feb;155(2):310-5.

13. Rosengren A, Hauptman PJ, Lappas G, et al. Big men and atrial fibrillation: effects of body size and weight gain on risk of atrial fibrillation in men. Eur Heart J. 2009 May;30(9):1113-20.

14. Tedrow UB, Conen D, Ridker PM, et al. The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation the WHS (women's health study). J Am Coll Cardiol. 2010 May 25;55(21):2319-27.

15. Badheka AO, Rathod A, Kizilbash MA, et al. Influence of obesity on outcomes in atrial fibrillation: yet another obesity paradox. Am J Med. 2010 Jul;123(7):646-51.

16. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol. 2009 May 26;53(21):1925-32.

17. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005 Oct 25;112(17):2735-52.

18. Watanabe H, Tanabe N, Watanabe T, et al. Metabolic Syndrome and Risk of Development of Atrial Fibrillation: The Niigata Preventive Medicine Study. Circulation. 2008 Apr 11;117(10):1255-60.

19. Nguyen JT, Benditt DG. Atrial fibrillation susceptibility in metabolic syndrome: simply the sum of its parts? Circulation. 2008 Mar 11;117(10):1249-51.

20. Fontes JD, Lyass A, Massaro JM, et al. Insulin resistance and atrial fibrillation (from the Framingham Heart Study). Am J Cardiol. 2012 Jan 1;109(1):87-90.

21. Nichols GA, Reinier K, Chugh SS. Independent contribution of diabetes to increased prevalence and incidence of atrial fibrillation. Diabetes Care. 2009 Oct;32(10):1851-6.

22. Dublin S, Glazer NL, Smith NL, et al. Diabetes mellitus, glycemic control, and risk of atrial fibrillation. J Gen Intern Med. 2010 Aug;25(8):853-8.

23. Huxley RR, Alonso A, Lopez FL, et al. Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the Atherosclerosis Risk in Communities study. Heart. 2012 Jan;98(2):133-8.

24. Huxley RR, Filion KB, Konety S, et al. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol. 2011 Jul 1;108(1):56-62.

25. Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation. 2001 Dec 11;104(24):2886-91.

26. Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation. 2003 Dec 16;108(24):3006-10.

27. Marott SC, Nordestgaard BG, Zacho J, et al. Does elevated C-reactive protein increase atrial fibrillation risk? A Mendelian randomization of 47,000 individuals from the general population. J Am Coll Cardiol. 2010 Aug 31;56(10):789-95.

28. Batal O, Schoenhagen P, Shao M, et al. Left atrial epicardial adiposity and atrial fibrillation. Circ Arrhythm Electrophysiol. 2010 Jun 1;3(3):230-6.

29. Tsao HM, Hu WC, Wu MH, et al. Quantitative analysis of quantity and distribution of epicardial adipose tissue surrounding the left atrium in patients with atrial fibrillation and effect of recurrence after ablation. Am J Cardiol. 2011 May 15;107(10):1498-503.

30. Mazurek T, Zhang L, Zalewski A, et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation. 2003 Nov 18;108(20):2460-6.

31. Al Chekakie MO, Welles CC, Metoyer R, et al. Pericardial fat is independently associated with human atrial fibrillation. J Am Coll Cardiol. 2010 Aug 31;56(10):784-8.

32. Shin SY, Yong HS, Lim HE, et al. Total and interatrial epicardial adipose tissues are independently associated with left atrial remodeling in patients with atrial fibrillation. J Cardiovasc Electrophysiol. 2011 Jun;22(6):647-55.

33. Thanassoulis G, Massaro JM, O'Donnell CJ, et al. Pericardial fat is associated with prevalent atrial fibrillation: the Framingham Heart Study. Circ Arrhythm Electrophysiol. 2010 Aug;3(4):345-50.

34. Wong CX, Abed HS, Molaee P, et al. Pericardial fat is associated with atrial fibrillation severity and ablation outcome. J Am Coll Cardiol. 2011 Apr 26;57(17):1745-51.

35. Chang LC, Huang KC, Wu YW, et al. The clinical implications of blood adiponectin in cardiometabolic disorders. J Formos Med Assoc. 2009 May;108(5):353-66.

36. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001 Jan 18;409(6818):307-12.

37. Mathiasen AB, Henningsen KM, Harutyunyan MJ, et al. YKL-40: a new biomarker in cardiovascular disease? Biomark Med. 2010 Aug;4(4):591-600.

38. Rathcke CN, Vestergaard H. YKL-40--an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc Diabetol. 2009;8:61.

39. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific

protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999 Apr 2;257(1):79-83.

40. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000 Jun;20(6):1595-9.

41. Ybarra J, Resmini E, Planas F, et al. Relationship between adiponectin and left atrium size in uncomplicated obese patients: adiponectin, a link between fat and heart. Obes Surg. 2009 Sep;19(9):1324-32.

42. Rienstra M, Sun JX, Lubitz SA, et al. Plasma resistin, adiponectin, and risk of incident atrial fibrillation: the Framingham Offspring Study. Am Heart J. 2012 Jan;163(1):119-24 e1.

43. Gungor H, Ayik MF, Kirilmaz B, et al. Serum resistin level: as a predictor of atrial fibrillation after coronary artery bypass graft surgery. Coron Artery Dis. 2011 Nov;22(7):484-90.

44. Kourliouros A, Karastergiou K, Nowell J, et al. Protective effect of epicardial adiponectin on atrial fibrillation following cardiac surgery. Eur J Cardiothorac Surg. 2011 Feb;39(2):228-32.

45. Henningsen KM, Therkelsen SK, Johansen JS, et al. Plasma YKL-40, a new biomarker for atrial fibrillation? Europace. 2009 Aug;11(8):1032-6.

46. Henningsen KM, Nilsson B, Johansen JS, et al. Plasma YKL-40 is elevated in patients with recurrent atrial fibrillation after catheter ablation. Inflamm Res. 2010 Jun;59(6):463-9.

47. Shimano M, Shibata R, Tsuji Y, et al. Circulating adiponectin levels in patients with atrial fibrillation. Circ J. 2008 Jul;72(7):1120-4.

48. Mihm MJ, Yu F, Carnes CA, et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation. 2001 Jul 10;104(2):174-80.

49. Iacobellis G, di Gioia CR, Cotesta D, et al. Epicardial adipose tissue adiponectin expression is related to intracoronary adiponectin levels. Horm Metab Res. 2009 Mar;41(3):227-31.

50. Kim YM, Guzik TJ, Zhang YH, et al. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ Res. 2005 Sep 30;97(7):629-36.

51. Lee SH, Chen YC, Chen YJ, et al. Tumor necrosis factor-alpha alters calcium handling and increases arrhythmogenesis of pulmonary vein cardiomyocytes. Life Sci. 2007 Apr 17;80(19):1806-15.

52. Gerritsen J, Dekker JM, TenVoorde BJ, et al. Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease: the Hoorn Study. Diabetes Care. 2001 Oct;24(10):1793-8.

53. Stevens MJ, Raffel DM, Allman KC, et al. Cardiac sympathetic dysinnervation in diabetes: implications for enhanced cardiovascular risk. Circulation. 1998 Sep 8;98(10):961-8.

54. Nordin C. The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence. Diabetologia. 2010 Aug;53(8):1552-61.

55. Gerstein HC, Miller ME, Genuth S, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011 Mar 3;364(9):818-28.

56. Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005 Jan 27;352(4):341-50.

57. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia. 1998 Apr;41(4):416-23.

58. Sacre JW, Franjic B, Jellis CL, et al. Association of cardiac autonomic neuropathy with subclinical myocardial dysfunction in type 2 diabetes. JACC Cardiovasc Imaging. 2010 Dec;3(12):1207-15.

59. Pop-Busui R, Kirkwood I, Schmid H, et al. Sympathetic dysfunction in type 1 diabetes: association with impaired myocardial blood flow reserve and diastolic dysfunction. J Am Coll Cardiol. 2004 Dec 21;44(12):2368-74.

60. Dimmer C, Tavernier R, Gjorgov N, et al. Variations of autonomic tone preceding onset of atrial fibrillation after coronary artery bypass grafting. Am J Cardiol. 1998 Jul 1;82(1):22-5.

61. Zipes DP, Mihalick MJ, Robbins GT. Effects of selective vagal and stellate ganglion stimulation of atrial refractoriness. Cardiovasc Res. 1974 Sep;8(5):647-55.

62. Spear JF, Moore EN. Influence of brief vagal and stellate nerve stimulation on pacemaker activity and conduction within the atrioventricular conduction system of the dog. Circ Res. 1973 Jan;32(1):27-41.

63. Goldberger AL, Pavelec RS. Vagally-mediated atrial fibrillation in dogs: conversion with bretylium tosylate. Int J Cardiol. 1986 Oct;13(1):47-55.

64. van den Berg MP, Hassink RJ, Balje-Volkers C, et al. Role of the autonomic nervous system in vagal atrial fibrillation. Heart. 2003 Mar;89(3):333-5.

65. Guler N, Ozkara C, Dulger H, et al. Do cardiac neuropeptides play a role in the occurrence of atrial fibrillation after coronary bypass surgery? Ann Thorac Surg. 2007 Feb;83(2):532-7.

66. Goette A. The vanishing story of angiotensin II receptor blockers in the treatment of atrial fibrillation. Europace. 2011 Apr;13(4):451-2.

67. Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol. 2008 Feb 26;51(8):802-9.

68. Kato T, Yamashita T, Sekiguchi A, et al. What are arrhythmogenic substrates in diabetic rat atria? J Cardiovasc Electrophysiol. 2006 Aug;17(8):890-4.

69. Otake H, Suzuki H, Honda T, et al. Influences of autonomic nervous system on atrial arrhythmogenic substrates and the incidence of atrial fibrillation in diabetic heart. Int Heart J. 2009 Sep;50(5):627-41.

70. Schmid H, Forman LA, Cao X, et al. Heterogeneous cardiac sympathetic denervation and decreased myocardial nerve growth factor in streptozotocin-induced diabetic rats: implications for cardiac sympathetic dysinnervation complicating diabetes. Diabetes. 1999 Mar;48(3):603-8.

71. Musial DC, de Magalhaes Galvao K, Miranda-Ferreira R, et al. Alteration of purinergic neurotransmission in isolated atria of streptozotocin-induced diabetic rats. J Cardiovasc Pharmacol. 2012 Feb;59(2):158-64.

72. Lok NS, Lau CP. Abnormal vasovagal reaction, autonomic function, and heart rate variability in patients with paroxysmal atrial fibrillation. Pacing Clin Electrophysiol. 1998 Feb;21(2):386-95.

73. van den Berg MP, Hassink RJ, Tuinenburg AE, et al. Impaired autonomic function predicts dizziness at onset of paroxysmal atrial fibrillation. Int J Cardiol. 2001 Dec;81(2-3):175-80.

74. Khand AU, Rankin AC, Cleland JG, et al. The assessment of autonomic function in chronic atrial fibrillation: description of a non-invasive technique based on circadian rhythm of atrioventricular nodal functional refractory periods. Europace. 2006 Nov;8(11):927-34.

75. Voulgari C, Tentolouris N, Stefanadis C. The ECG vertigo in diabetes and cardiac autonomic neuropathy. Exp Diabetes Res. 2011;2011:687624.

76. Bissinger A, Grycewicz T, Grabowicz W, et al. The effect of diabetic autonomic neuropathy on P-wave duration, dispersion and atrial fibrillation. Arch Med Sci. 2011 Oct;7(5):806-12.

77. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology. 2007 Aug 7;69(6):546-54.

78. Dentali F, Squizzato A, Ageno W. The metabolic syndrome as a risk factor for venous and arterial thrombosis. Semin Thromb Hemost. 2009 Jul;35(5):451-7.

79. Palomo I, Moore-Carrasco R, Alarcon M, et al. Pathophysiology of the proatherothrombotic state in the metabolic syndrome. Front Biosci (Schol Ed). 2010;2:194-208.

80. Hulthe J, Bokemark L, Wikstrand J, et al. The metabolic syndrome, LDL particle size, and atherosclerosis: the Atherosclerosis and Insulin Resistance (AIR) study. Arterioscler Thromb Vasc Biol. 2000 Sep;20(9):2140-7.

81. Bowles LK, Cooper JA, Howarth DJ, et al. Associations of haemostatic variables with body mass index: a community-based study. Blood Coagul Fibrinolysis. 2003 Sep;14(6):569-73.

82. Darvall KA, Sam RC, Silverman SH, et al. Obesity and thrombosis. Eur J Vasc Endovasc Surg. 2007 Feb;33(2):223-33.

83. Stegenga ME, van der Crabben SN, Blumer RM, et al. Hyperglycemia enhances coagulation and reduces neutrophil degranulation, whereas hyperinsulinemia inhibits fibrinolysis during human endotoxemia. Blood. 2008 Jul 1;112(1):82-9.

84. Rao AK, Chouhan V, Chen X, et al. Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men. Diabetes. 1999 May;48(5):1156-61.

85. Khechai F, Ollivier V, Bridey F, et al. Effect of advanced glycation end product-modified albumin on tissue factor expression by monocytes. Role of oxidant stress and protein tyrosine kinase activation. Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2885-90.

86. Min C, Kang E, Yu SH, et al. Advanced glycation end products induce apoptosis and procoagulant activity in cultured human umbilical vein endothelial cells. Diabetes Res Clin Pract. 1999 Dec;46(3):197-202.

87. Ceriello A, Giugliano D, Quatraro A, et al. Blood glucose may condition factor VII levels in diabetic and normal subjects. Diabetologia. 1988 Dec;31(12):889-91.

88. Reid HL, Vigilance J, Wright-Pascoe RA, et al. The influence of persistent hyperglycaemia on hyperfibrinogenaemia and hyperviscosity in diabetes mellitus. West Indian Med J. 2000 Dec;49(4):281-4.

89. Fain JN, Madan AK. Insulin enhances vascular endothelial growth factor, interleukin-8, and plasminogen activator inhibitor 1 but not interleukin-6 release by human adipocytes. Metabolism. 2005 Feb;54(2):220-6.

90. Gami AS, Pressman G, Caples SM, et al. Association of atrial fibrillation and obstructive sleep apnea. Circulation. 2004 Jul 27;110(4):364-7.

91. Vericel E, Januel C, Carreras M, et al. Diabetic patients without vascular complications display enhanced basal platelet activation and decreased antioxidant status. Diabetes. 2004 Apr;53(4):1046-51.

92. Aghamohammadzadeh R, Withers SB, Lynch FM, et al. Perivascular adipose tissue from human systemic and coronary vessels: The emergence of a new pharmacotherapeutic target. Br J Pharmacol. 2011 May 13.

93. Nakata M, Yada T, Soejima N, et al. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes. 1999 Feb;48(2):426-9.

94. Kato H, Kashiwagi H, Shiraga M, et al. Adiponectin acts as an endogenous antithrombotic factor. Arterioscler Thromb Vasc Biol. 2006 Jan;26(1):224-30.

95. Shoji T, Koyama H, Fukumoto S, et al. Platelet activation is associated with hypoadiponectinemia and carotid atherosclerosis. Atherosclerosis. 2006 Sep;188(1):190-5.

96. Hughes M, Lip GY. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost. 2008 Feb;99(2):295-304.

97. 97.   Lip GY, Halperin JL. Improving stroke risk stratification in atrial fibrillation. Am J Med. 2010 Jun;123(6):484-8.

98. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010 Oct;12(10):1360-420.

99. Tang RB, Liu XH, Kalifa J, et al. Body mass index and risk of left atrial thrombus in patients with atrial fibrillation. Am J Cardiol. 2009 Dec 15;104(12):1699-703.

100. Xu G, Chen J, Jing G, et al. Preventing beta-Cell Loss and Diabetes With Calcium Channel Blockers. Diabetes. 2012 Apr;61(4):848-56.

101. Wood MA, Brown-Mahoney C, Kay GN, et al. Clinical outcomes after ablation and pacing therapy for atrial fibrillation : a meta-analysis. Circulation. 2000 Mar 14;101(10):1138-44.

102. Frick M, Frykman V, Jensen-Urstad M, et al. Factors predicting success rate and recurrence of atrial fibrillation after first electrical cardioversion in patients with persistent atrial fibrillation. Clin Cardiol. 2001 Mar;24(3):238-44.

103. Elhendy A, Gentile F, Khandheria BK, et al. Predictors of unsuccessful electrical cardioversion in atrial fibrillation. Am J Cardiol. 2002 Jan 1;89(1):83-6.

104. Blich M, Edoute Y. Electrical cardioversion for persistent or chronic atrial fibrillation: outcome and clinical factors predicting short and long term success rate. Int J Cardiol. 2006 Mar 8;107(3):389-94.

105. Daousi C, Casson IF, Gill GV, et al. Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgrad Med J. 2006 Apr;82(966):280-4.

106. Saliba W, Juratli N, Chung MK, et al. Higher energy synchronized external direct current cardioversion for refractory atrial fibrillation. J Am Coll Cardiol. 1999 Dec;34(7):2031-4.

107. Botto GL, Politi A, Bonini W, et al. External cardioversion of atrial fibrillation: role of paddle position on technical efficacy and energy requirements. Heart. 1999 Dec;82(6):726-30.

108. Mehdirad AA, Clem KL, Love CJ, et al. Improved clinical efficacy of external cardioversion by fluoroscopic electrode positioning and comparison to internal cardioversion in patients with atrial fibrillation. Pacing Clin Electrophysiol. 1999 Jan;22(1 Pt 2):233-7.

109. Schmitt C, Alt E, Plewan A, et al. Low energy intracardiac cardioversion after failed conventional external cardioversion of atrial fibrillation. J Am Coll Cardiol. 1996 Oct;28(4):994-9.

110. Chao TF, Suenari K, Chang SL, et al. Atrial substrate properties and outcome of catheter ablation in patients with paroxysmal atrial fibrillation associated with diabetes mellitus or impaired fasting glucose. Am J Cardiol. 2010 Dec 1;106(11):1615-20.

111. Forleo GB, Mantica M, De Luca L, et al. Catheter ablation of atrial fibrillation in patients with diabetes mellitus type 2: results from a randomized study comparing pulmonary vein isolation versus antiarrhythmic drug therapy. J Cardiovasc Electrophysiol. 2009 Jan;20(1):22-8.

112. Tang RB, Dong JZ, Liu XP, et al. Safety and efficacy of catheter ablation of atrial fibrillation in patients with diabetes mellitus--single center experience. J Interv Card Electrophysiol. 2006 Oct;17(1):41-6.

113. Park JH, Pak HN, Kim SK, et al. Electrophysiologic characteristics of complex fractionated atrial electrograms in patients with atrial fibrillation. J Cardiovasc Electrophysiol. 2009 Mar;20(3):266-72.

114. Cai L, Yin Y, Ling Z, et al. Predictors of late recurrence of atrial fibrillation after catheter ablation. Int J Cardiol. 2011 Jul 6.

115. Shiroshita-Takeshita A, Brundel BJ, Nattel S. Atrial fibrillation: basic mechanisms, remodeling and triggers. J Interv Card Electrophysiol. 2005 Sep;13(3):181-93.

116. Boos C, Ritzema J, More RS. A short course of oral amiodarone improves sinus rhythm maintenance post-cardioversion for atrial fibrillation. Heart. 2004 Sep;90(9):1063-4.

117. Korantzopoulos P, Kolettis TM, Galaris D, et al. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int J Cardiol. 2007 Feb 7;115(2):135-43.

118. Shimano M, Shibata R, Inden Y, et al. Reactive oxidative metabolites are associated with atrial conduction disturbance in patients with atrial fibrillation. Heart Rhythm. 2009 Jul;6(7):935-40.

119. Kumar S, Sutherland F, Morton JB, et al. Long-term omega-3 polyunsaturated fatty acid supplementation reduces the recurrence of persistent atrial fibrillation after electrical cardioversion. Heart Rhythm. 2011 Nov 23.

120. Boos CJ, Lip GY. Inflammation and atrial fibrillation: cause or effect? Heart. 2008 Feb;94(2):133-4.

121. Richter B, Derntl M, Marx M, et al. Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation

outcome after ablation of atrial fibrillation. Am Heart J. 2007 Jan;153(1):113-9.

122. Patel D, Mohanty P, Di Biase L, et al. The impact of statins and renin-angiotensin-aldosterone system blockers on pulmonary vein antrum isolation outcomes in post-menopausal females. Europace. 2010 Mar;12(3):322-30.

123. Tayebjee MH, Creta A, Moder S, et al. Impact of angiotensin-converting enzyme-inhibitors and angiotensin receptor blockers on long-term outcome of catheter ablation for atrial fibrillation. Europace. 2010 Nov;12(11):1537-42.

124. Nodari S, Triggiani M, Campia U, et al. n-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: a prospective, randomized study. Circulation. 2011 Sep 6;124(10):1100-6.

125. Farquharson AL, Metcalf RG, Sanders P, et al. Effect of dietary fish oil on atrial fibrillation after cardiac surgery. Am J Cardiol. 2011 Sep 15;108(6):851-6.

126. Kowey PR, Reiffel JA, Ellenbogen KA, et al. Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial. Jama. 2010 Dec 1;304(21):2363-72.

127. Frost L, Vestergaard P. n-3 Fatty acids consumed from fish and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Clin Nutr. 2005 Jan;81(1):50-4.

128. Gu J, Liu X, Wang X, et al. Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus. Europace. 2011 Sep;13(9):1256-61.

129. Giannini S, Serio M, Galli A. Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity. J Endocrinol Invest. 2004 Nov;27(10):982-91.

130. Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost. 2010 Jul;104(1):49-60.

131. Qayyum R, Adomaityte J. Meta-analysis of the effect of thiazolidinediones on serum C-reactive protein levels. Am J Cardiol. 2006 Mar 1;97(5):655-8.

132. Heneghan HM, Meron-Eldar S, Brethauer SA, et al. Effect of Bariatric Surgery on Cardiovascular Risk Profile. 2011 Aug 29.

133. Nicholas C, May R. HealthGrades Fifth Annual Bariatric Surgery Trends in American Hospitals Study2010.

134. Sola E, Vaya A, Espana F, et al. Plasminogen activator inhibitor-1 levels in severe and morbid obesity. Effect of weight loss and influence of 4G/5G polymorphism. Thromb Res. 2008;122(3):320-7.